PCOM Library / Hot Topics in Research / Hot Topics: First Tardive Dyskinesia Drug Approved by FDA

Hot Topics: First Tardive Dyskinesia Drug Approved by FDA

Jackie Werner Hot Topics in Research, Neurology, Psychology and Psychiatry

FDA approves first drug to treat tardive dyskinesia

Food and Drug Administration, U.S. Department of Health and Human Services. (2017). FDA approves first drug to treat tardive dyskinesia. Retrieved fromĀ https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm552418.htm.

The U.S. Food and Drug Administration today [April 11, 2017] approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition.

Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips. Some affected people also experience involuntary movement of the extremities or difficulty breathing.